| 书目名称 | Safety of Biologics Therapy | | 副标题 | Monoclonal Antibodie | | 编辑 | Brian A. Baldo | | 视频video | | | 概述 | The only book available that covers in a single volume the full range of issues surrounding safety of approved biologic therapies.In addition to presenting a detailed examination of adverse effects an | | 图书封面 |  | | 描述 | .This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world‘s 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world‘s 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind,.Safety of Biologics Therapy. examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern bi | | 出版日期 | Book 2016 | | 关键词 | antibodies; insulin; mABS; theraputic agents; chimeric fusion proteins; cytokines; hormones; enzymes | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-319-30472-4 | | isbn_softcover | 978-3-319-80819-2 | | isbn_ebook | 978-3-319-30472-4 | | copyright | Springer International Publishing Switzerland 2016 |
The information of publication is updating
|
|
发表于 2025-3-21 16:06:35
